Impact of septic episodes caused by Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa in a tertiary hospital: clinical and economic considerations in years 2018-2020.


Journal

Journal of infection and public health
ISSN: 1876-035X
Titre abrégé: J Infect Public Health
Pays: England
ID NLM: 101487384

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 19 12 2022
revised: 17 01 2023
accepted: 07 02 2023
pubmed: 22 2 2023
medline: 21 3 2023
entrez: 21 2 2023
Statut: ppublish

Résumé

To evaluate incidence, therapy and antibiotic resistance trends in septic episodes caused by three multi-drug resistant bacteria in a tertiary hospital, by also estimating their economic impact. An observational, retrospective-cohort analysis was based on data related to patients admitted to the "SS. Antonio e Biagio e Cesare Arrigo" Hospital in Alessandria (Italy) between 2018 and 2020, that developed sepsis from multi-drug resistant bacteria of the examined species. Data were retrieved from medical records and from the hospital's management department. Inclusion criteria led to enrolment of 174 patients. A relative increase in A. baumannii cases (p < 0.0001) and an increasing resistance trend for K. pneumoniae (p < 0.0001) were detected in 2020 compared to 2018-2019. Most patients were treated with carbapenems (72.4%), although the use of colistin rose significantly in 2020 (62.5% vs 36%, p = 0.0005). Altogether, these 174 cases caused 3295 additional hospitalisation days (mean 19 days/patient): the consequent expenditure attained ≈ 3 million Euros, 85% of which (≈2.5 million Euros) due to the cost of extra hospital stay. Specific antimicrobial therapy accounted for 11.2% of the total (≈336,000 €). Healthcare-related septic episodes cause a considerable burden. Moreover, a trend could be spotted towards higher relative incidence of complex cases recently.

Identifiants

pubmed: 36801627
pii: S1876-0341(23)00037-0
doi: 10.1016/j.jiph.2023.02.007
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

475-482

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Jacopo Garlasco (J)

Department of Public Health Sciences and Paediatrics, University of Turin, Turin, Italy. Electronic address: jacopo.garlasco@unito.it.

Iva Beqiraj (I)

School of Medicine, "Amedeo Avogadro" University of Eastern Piedmont, Novara, Italy.

Cesare Bolla (C)

Department of Infectious Diseases, "SS. Antonio e Biagio e Cesare Arrigo" Hospital, Alessandria, Italy.

Elisabeth Maria Irene Marino (EMI)

Infection Prevention and Control Unit, "SS. Antonio e Biagio e Cesare Arrigo" Hospital, Alessandria, Italy.

Cristian Zanelli (C)

Department of Management Control, "SS. Antonio e Biagio e Cesare Arrigo" Hospital, Alessandria, Italy.

Corrado Gualco (C)

Department of Management Control, "SS. Antonio e Biagio e Cesare Arrigo" Hospital, Alessandria, Italy.

Andrea Rocchetti (A)

Department of Microbiology, "SS. Antonio e Biagio e Cesare Arrigo" Hospital, Alessandria, Italy.

Maria Michela Gianino (MM)

Department of Public Health Sciences and Paediatrics, University of Turin, Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH